Projects per year
Project Details
Description
The overarching goal of the Prometheus consortium is to develop antibody-based
prophylactics and therapeutics against three major groups of Category A priority viruses
that cause zoonotic disease—ebolaviruses, the nairovirus Crimean-Congo hemorrhagic fever
virus (CCHFV), the New-World hantaviruses Andes virus (ANDV) and Sin Nombre virus (SNV),
and the Old-World hantavirus Puumula virus (PUUV). The Administrative Core, Core A, will serve
as the hub for Prometheus, providing governance, personnel, and resources for all program
management arms, including administrative, financial, performance monitoring and reporting,
compliance, project and team coordination, internal and external communication, resource and
change management, and intellectual property management. Albert Einstein College of Medicine
(Einstein) will serve as the lead institution for the Prometheus CETR and bear overall
responsibility for its performance. To achieve these goals and advance Prometheus’s strategic
research plan, we will develop and implement plans to: (1) organize, oversee, monitor, and report
Prometheus activities; (2) foster team interaction and coordination; (3) communicate the CETR’s
mission and activities to the scientific community and the public; and (4) manage travel, conflict,
change, risk, intellectual property, and resources and reagents.
Status | Finished |
---|---|
Effective start/end date | 3/1/19 → 1/31/24 |
Funding
- National Institute of Allergy and Infectious Diseases: $202,273.00
- National Institute of Allergy and Infectious Diseases: $290,847.00
- National Institute of Allergy and Infectious Diseases: $213,723.00
- National Institute of Allergy and Infectious Diseases: $175,492.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
Projects
- 1 Finished